ESR1 and breast carcinoma: Tamoxifen impacts the binding of cyclin D1 with ER and STAT3 in cyclin D1-overexpressing breast cancer cells, abolishing cyclin D1-mediated inhibition of STAT3 and growth suppression, allowing STAT3 to exhibit anti-apoptotic activity.